BlackRock, Inc. 13D and 13G filings for Relmada Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-07-07 4:35 pm Sale |
2023-06-30 | 13G | Relmada Therapeutics, Inc. RLMD |
BlackRock Inc. BLK |
605,254 2.000% |
-1,257,888 (-67.51%) |
Filing |
| 2023-02-01 4:54 pm Purchase |
2022-12-31 | 13G | Relmada Therapeutics, Inc. RLMD |
BlackRock Inc. BLK |
1,863,142 6.200% |
477,907 (+34.50%) |
Filing |
| 2022-02-03 4:41 pm Sale |
2021-12-31 | 13G | Relmada Therapeutics, Inc. RLMD |
BlackRock Inc. BLK |
1,385,235 5.200% |
-107,784 (-7.22%) |
Filing |
| 2021-02-02 3:13 pm Purchase |
2020-12-31 | 13G | Relmada Therapeutics, Inc. RLMD |
BlackRock Inc. BLK |
1,493,019 9.200% |
1,493,019 (New Position) |
Filing |